Cancer is one of the major causes of death in spite of a substantial increase in understanding of the molecular mechanism behind its occurrence. Glioma is the type of brain tumour which arises in the glial cells of the brain. Glioma is categorized into three areas namely: astrocytoma, oligodendroglioma and astro-oligodendroglioma (mixture of both). Every year in UK approximately 2% of the brain tumour patient are diagnosed with glioma therefore, it is very important to find a remedy for treatment of this cancer. One of the interesting properties of liposomes is their natural ability to target tumour. It is the most extensively used biodegradable carriers and regarded as the most promising ones in drug delivery (Katare et al., 1990; Crommelin and Sindelar, 2002). Liposomes are very safe adjuvants as they are manufactured from phospholipids that are similar to the phospholipids present in the biological membranes. Unfortunately, liposomes are chemically and physically unstable and are difficult to manufacture on a large scale using the conventional method of preparation (thin film method). However, these stability problems can be avoided by formulating liposomes using the proliposome method. Proliposomes are of two types, namely, particulate-based proliposomes and solvent-based proliposomes. Particulate proliposomes are dry, free-flowing carrier particles coated with phospholipids that generate liposomes on addition of aqueous phase (Payne et al 1986). Secondly, a solvent based proliposome method offers a relatively simple means of generating liposomes with a high entrapment of hydrophilic agents, by the addition of aqueous phase to a concentrated alcoholic solution of phospholipids (Perrett et al 1991). The aim of our project is to use phospholipids to manufacture solvent-based proliposomes which can be used to generate phospholipid vesicles (liposomes) when aqueous phase (e.g. water) is added. Various phospholipids will be investigated and the resultant size of the vesicles will be compared with the conventional method of producing liposomes. The model anticancer drugs will be entrapped in liposomes and the efficacy of anticancer-liposome formulations on the viability of glioma cell lines and molecular mechanism of the cell death will be investigated.